BioMarin Pharma (BMRN) Tops Q1 EPS by 46c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.69 --0%
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.63, $0.46 better than the analyst estimate of $0.17. Revenue for the quarter came in at $519 million versus the consensus estimate of $507.52 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
